Genprex, Inc. (GNPX) stock
Close on Nov 12, 2026Market cap $1.81MP/E –Yield –
Key statistics
Valuation at the latest close; fundamentals over fiscal , balances at Jun 30, 2026
Valuation
- Market cap
- $1.81M
- P/E ratio
- –
- Price to sales
- –
- Price to book
- 0.12
- Dividend yield
- –
- Free cash flow yield
- –
Fundamentals
- Net income
- -$16.50M
- Book value per share
- $31.27
- Diluted shares
- 0M
Trading
- Previous close
- $2.29
- Open
- $2.30
- Day's range
- $2.20 – $2.30
- Volume
- 19,038
- Average volume (20 days)
- 165,495
- Beta (5 years)
- 0.62
- 52-week range
- $1.71 – $110.01
- RSI (14 days)
- 48.0
- Volatility (1 year)
- 106.4%
- Relative volume
- 0.72×
- WACC
- 8.0%
Market cap history
Month-end market cap since 2018, using shares outstanding reported at the time
Total return vs. the S&P 500
Price change plus reinvested dividends, to the close on Nov 12, 2026. The S&P 500 is measured by the SPY fund.
| Period | GNPX | S&P 500 | Difference | GNPX per year | S&P 500 per year |
|---|---|---|---|---|---|
| 1 month | -17.8% | -2.7% | −15.1 pts | ||
| 3 months | -53.3% | -1.7% | −51.5 pts | ||
| Year to date | -94.3% | +11.9% | −106.2 pts | ||
| 1 year | -97.8% | +12.0% | −109.8 pts | ||
| 3 years | -100.0% | +78.2% | −178.2 pts | -93.9% | +21.2% |
| 5 years | -100.0% | +73.2% | −173.2 pts | -88.1% | +11.6% |
Eleven years at a glance
Fiscal years 2015 to 2025 and trailing twelve months, USD
Revenue
Operating income
Net income
EPS, diluted
Free cash flow
Press releases
Releases Genprex filed with the SEC as exhibits to Form 8-K or 6-K
- Update
- Update
- Update
- News
- News
- Update
About Genprex
Pharmaceutical Preparations
The company is a clinical-stage biotechnology firm focused on developing gene therapies for oncology and diabetes. Its oncology pipeline relies on its proprietary ONCOPREX Delivery System, an intravenous, non-viral nanoparticle platform that carries tumor suppressor genes directly to cancer cells. The lead drug candidate, REQORSA (quaratusugene ozeplasmid), administers the TUSC2 gene and is under clinical investigation in combination with standard therapies for non-small cell lung cancer and small cell lung cancer. In diabetes, the company develops GPX-002, a preclinical candidate engineered to restore insulin generation in type 1 and type 2 diabetes. Its potential end users are patients suffering from advanced lung cancers and diabetes.
Company profile, executives and historyGenprex stock: common questions
What is Genprex's stock price?
GNPX closed at $2.21 on Nov 12, 2026, down 3.49% on the day. Over the past 52 weeks it traded between $1.71 and $110.01.
What is Genprex's market cap?
Genprex was worth $1.81M at the close on Nov 12, 2026: the share price times the diluted shares outstanding.
Does Genprex pay a dividend?
No. Genprex has not paid a cash dividend over the last twelve months.
How has GNPX stock performed over the past year?
Including dividends, GNPX returned -97.8% over the past year, against +12.0% for the S&P 500.
How many GNPX shares are sold short?
0M shares were sold short at the latest FINRA report, 16.79% of the float, or 1.0 days of average trading volume.
Who are Genprex's competitors?
Companies most similar to Genprex by business, industry and size include RNAZ, FHTX, PGEN, PHIO, CLRB.
See a number that looks wrong?